Skip to main content
SpringerLink
Log in

Dermatologic Adverse Effects of Anticancer Therapy II: Cytotoxic Agents

  • Chapter
  • First Online:
Dermato-Oncology Study Guide

  • 375 Accesses

Abstract

This chapter explores cytotoxic therapies and various dermatologic adverse effects (DAEs) from their use. Medications featured here provide an overview of indications for each drug class as well as profiles of their potential mucocutaneous reactions. For each anticancer agent, a clinical summary is provided, offering an a overview of incidence, natural course, clinical features, and management of its dermatologic adverse effects. This chapter is designed to assist practitioners in anticipating the dermatologic manifestations of these anticancer therapies and managing any complications should they arise.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. de Jonge ME, Mathôt RA, Dalesio O, Huitema AD, Rodenhuis S, Beijnen JH. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy. Bone Marrow Transplant. 2002;30(9):593–7.

    Article  PubMed  Google Scholar 

  2. Kim KJ, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. Periungal hyperpigmentation induced by cisplatin. Clin Exp Dermatol. 2002;27(2):118–9.

    Article  PubMed  CAS  Google Scholar 

  3. Sroa N, Bartholomew DA, Magro CM. Lipodermatosclerosis as a form of vascular compromise-associated radiation recall dermatitis: case report and a review of literature. J Cutan Pathol. 2006;33(Suppl 2):55–9.

    Article  PubMed  Google Scholar 

  4. Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the "red man". Clin Dermatol. 2005;23(2):206–17.

    Article  PubMed  Google Scholar 

  5. Brodsky A, Aparici I, Argeri C, Goldenberg D. Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity. J Clin Pharmacol. 1989;29(9):821–3.

    Article  PubMed  CAS  Google Scholar 

  6. Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol. 1996;26(2):105–10.

    Article  PubMed  CAS  Google Scholar 

  7. Altwerger G, Gressel GM, English DP, Nelson WK, Carusillo N, Silasi DA, Azodi M, Santin A, Schwartz PE, Ratner ES. Platinum desensitization in patients with carboplatin hypersensitivity: a single-institution retrospective study. Gynecol Oncol. 2017;144(1):77–82.

    Article  PubMed  CAS  Google Scholar 

  8. Kähler KC, Mustroph D, Hauschild A. Current recommendations for prevention and therapy of extravasation reactions in dermato-oncology. J Dtsch Dermatol Ges. 2009;7(1):21–8.

    PubMed  Google Scholar 

  9. Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14(2):212–6.

    Article  PubMed  CAS  Google Scholar 

  10. Brauer MJ, McEvoy BF, Mitus WJ. Hypersensitivity to nitrogen mustards in the form of erythema multiforme. A unique adverse reaction. Arch Intern Med. 1967;120(4):499–503.

    Article  PubMed  CAS  Google Scholar 

  11. Kovalyshyn I, Bijal AD, Lacouture ME, Brownell I. Cyclophosphamide-associated acneiform drug eruption in a patient with multiple myeloma. J Am Acad Dermatol. 2011;65(3):657–9.

    Article  PubMed  Google Scholar 

  12. Gottlieb D, Commens C. Recurrent “flare” of dermatitis herpetiformis after cytotoxic therapy for malignant lymphoma. Med J Aust. 1986;145(5):241.

    Article  PubMed  CAS  Google Scholar 

  13. Bargman HB, Fefferman I. Multiple dermatofibromas in a patient with myasthenia gravis treated with prednisone and cyclophosphamide. J Am Acad Dermatol. 1986;14:351–2.

    Article  PubMed  CAS  Google Scholar 

  14. Valks R, Fraga J, Porras-Luque J, Figuera A, Garcia-Diéz A, Fernändez-Herrera J. Chemotherapy-induced eccrine squamous syringometaplasia. A distinctive eruption in patients receiving hematopoietic progenitor cells. Arch Dermatol. 1997;133(7):873–8.

    Article  PubMed  CAS  Google Scholar 

  15. Lienesch DW, Mutasim DF, Singh RR. Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient: a complication of cyclophosphamide. Lupus. 2003;12(9):707–9.

    Article  PubMed  CAS  Google Scholar 

  16. Borroni G, Vassallo C, Brazzelli V, Martinoli S, Ardigò M, Alessandrino PE, Borroni RG, Franchini P. Radiation recall dermatitis, panniculitis, and myositis following cyclophosphamide therapy: histopathologic findings of a patient affected by multiple myeloma. Am J Dermatopathol. 2004;26(3):213–6.

    Article  PubMed  Google Scholar 

  17. Assier-Bonnet H, Aractingi S, Cadranel J, Wechsler J, Mayaud C, Saiag P. Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. Br J Dermatol. 1996;135(5):864–6.

    Article  PubMed  CAS  Google Scholar 

  18. Green RM, Schapel GJ, Sage RE. Cutaneous vasculitis due to cyclophosphamide therapy for chronic lymphocytic leukemia. Aust NZ J Med. 1989;19(1):55–7.

    Article  CAS  Google Scholar 

  19. Landau M, Brenner S, Gat A, Klausner JM, Gutman M. Reticulate scleroderma after isolated limb perfusion with melphalan. J Am Acad Dermatol. 1998;39(6):1011–2.

    Article  PubMed  CAS  Google Scholar 

  20. Vaida I, Roszkiewicz F, Gruson B, Makdassi R, Damaj G. Drug rash with eosinophilia and systemic symptoms after chlorambucil treatment in chronic lymphocytic leukaemia. Pharmacology. 2009;83(3):148–9.

    Article  PubMed  CAS  Google Scholar 

  21. Hitchins RN, Hocker GA, Thomson DB. Chlorambucil allergy—a series of three cases. Aust NZ J Med. 1987;17(6):600–2.

    Article  CAS  Google Scholar 

  22. Kilickap S, Kurt M, Aksoy S, Erman M, Turker A. Extensive exfoliative dermatitis induced by chlorambucil. Am J Hematol. 2006;81(11):891–2.

    Article  PubMed  Google Scholar 

  23. Clark E, Boffa M, Magri C, Muscat V. Chlorambucil-induced radiation recall dermatitis. Skinmed. 2015;13(4):317–9.

    PubMed  Google Scholar 

  24. Barone C, Cassano A, Astone A. Toxic epidermal necrolysis during chlorambucil therapy in chronic lymphocytic leukaemia. Eur J Cancer (Oxford, England: 1990). 1990;26(11–12):1262.

    Article  CAS  Google Scholar 

  25. Harber ID, Adams KV, Casamiquela K, Helms S, Benson BT, Herrin V. Bendamustine-induced acute generalized Exanthematous Pustulosis confirmed by patch testing. Dermatitis. 2017;28(4):292–3.

    Article  PubMed  Google Scholar 

  26. Carilli A, Favis G, Sundharkrishnan L, Hajdenberg J. Severe dermatologic reactions with bendamustine: a case series. Case Rep Oncol. 2014;7(2):465–70.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Gavini A, Telang GH, Olszewski AJ. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. Int J Hematol. 2012;95(3):311–4.

    Article  PubMed  Google Scholar 

  28. Rosman IS, Lloyd BM, Hayashi RJ, Bayliss SJ. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58(4):575–8.

    Article  PubMed  Google Scholar 

  29. Harben DJ, Cooper PH, Rodman OG. Thiotepa-induced leukoderma. Arch Dermatol. 1979;115(8):973–4.

    Article  PubMed  CAS  Google Scholar 

  30. Ritch PS, Louie AC. Skin rash following therapy with mitomycin C. Cancer. 1984;54(1):32–3.

    Article  PubMed  CAS  Google Scholar 

  31. Arikawa S, Uchida M, Ogoh E, Uozumi J, Yoshida S, Watanabe Y, Kaida H, Ishibashi N, Shirouzu K, Hayabuchi N. Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal. Gan to kagaku ryoho. Cancer Chemother. 2010;37(4):727–30.

    Google Scholar 

  32. Spencer HJ. Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil. J Surg Oncol. 1984;26(1):47–50.

    Article  PubMed  CAS  Google Scholar 

  33. Andreu-Barasoain M, Gómez de la Fuente E, Pinedo F, Nuño A, López-Estebaranz JL. Intravesical mitomycin C-induced generalized pustular folliculitis. J Am Acad Dermatol. 2012;67(4):e142–3.

    Article  PubMed  Google Scholar 

  34. Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol. 2011;11(4):313–8.

    Article  PubMed  Google Scholar 

  35. Khong JJ, Muecke J. Complications of mitomycin C therapy in 100 eyes with ocular surface neoplasia. Br J Ophthalmol. 2006;90(7):819–22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. de Groot AC, Conemans JM. Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C. Contact Dermatitis. 1991;24(3):201–9.

    Article  PubMed  Google Scholar 

  37. Kunkeler L, Nieboer C, Bruynzeel DP. Type III and type IV hypersensitivity reactions due to mitomycin C. Contact Dermatitis. 2000;42(2):74–6.

    Article  PubMed  CAS  Google Scholar 

  38. Sanchis JM, Bagán JV, Gavaldá C, Murillo J, Diaz JM. Erythema multiforme: diagnosis, clinical manifestations and treatment in a retrospective study of 22 patients. J Oral Pathol Med. 2010;39(10):747–52.

    Article  PubMed  CAS  Google Scholar 

  39. Bronner AK, Hood AF. Cutaneous complications of chemotherapeutic agents. J Am Acad Dermatol. 1983;9(5):645–63.

    Article  PubMed  CAS  Google Scholar 

  40. Kyle RA, Dameshek W. Porthyria Cutanea Tarda associated with chronic granulocytic leukemia treated with Busulfan (Myleran). Blood. 1964;23:776–85.

    Article  PubMed  CAS  Google Scholar 

  41. Bandini G, Belardinelli A, Rosti G, Calori E, Motta MR, Rizzi S, Benini C, Tura S. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant. 1994;13(5):577–81.

    PubMed  CAS  Google Scholar 

  42. Granstein RD, Sober AJ. Drug- and heavy metal—induced hyperpigmentation. J Am Acad Dermatol. 1981;5(1):1–18.

    Article  PubMed  CAS  Google Scholar 

  43. Burns WA, McFarland W, Matthews MJ. Toxic manifestations of busulfan therapy. Med Ann Dist Columbia. 1971;40(9):567–72.

    PubMed  CAS  Google Scholar 

  44. Shear NH, Knowles SR, Shapiro L, Poldre P. Dapsone in prevention of recurrent neutrophilic eccrine hidradenitis. J Am Acad Dermatol. 1996;35(5.2):819–22.

    Article  PubMed  CAS  Google Scholar 

  45. Rosen AC, Balagula Y, Raisch DW, Garg V, Nardone B, Larsen N, Sorrell J, West DP, Anadkat MJ, Lacouture ME. Life-threatening dermatologic adverse events in oncology. Anti-Cancer Drugs. 2014;25(2):225–34.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Wilkin JK. Flushing reactions in the cancer chemotherapy patient. The lists are longer but the strategies are the same. Arch Dermatol. 1992;128(10):1387–9.

    Article  PubMed  CAS  Google Scholar 

  47. Glovsky MM, Braunwald J, Opelz G, Alenty A. Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum complement activity. J Allergy Clin Immunol. 1976;57(2):134–40.

    Article  PubMed  CAS  Google Scholar 

  48. Giguere JK, Douglas DM, Lupton GP, Baker JR, Weiss RB. Procarbazine hypersensitivity manifested as a fixed drug eruption. Med Pediatr Oncol. 1988;16(6):378–80.

    Article  PubMed  CAS  Google Scholar 

  49. Treudler R, Georgieva J, Geilen CC, Orfanos CE. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. J Am Acad Dermatol. 2004;50(5):783–5.

    Article  PubMed  Google Scholar 

  50. Koehn GG, Balizet LB. Unusual local cutaneous reaction to dacarbazine. Arch Dermatol. 1982;118(12):1018–9.

    Article  PubMed  CAS  Google Scholar 

  51. Roider E, Schneider J, Flaig MJ, Ruzicka T, Kunte C, Berking C. Hypopigmentation in the sites of regressed melanoma metastases after successful dacarbazine therapy. Int J Dermatol. 2012;51(9):1142–4.

    Article  PubMed  Google Scholar 

  52. Johnson TM, Rapini RP, Duvic M. Inflammation of actinic keratoses from systemic chemotherapy. J Am Acad Dermatol. 1987;17(2.1):192–7.

    Article  PubMed  CAS  Google Scholar 

  53. Kennedy RD, McAleer JJ. Radiation recall dermatitis in a patient treated with dacarbazine. Clin Oncol (R Coll Radio). 2001;13(6):470–2.

    CAS  Google Scholar 

  54. Okada M, Miyake K, Shinomiya A, Kawai N, Tamiya T. Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma. J Neurosurg. 2013;118(2):258–63.

    Article  PubMed  Google Scholar 

  55. Kanat O, Baskan BE, Kurt E, Evrensel T. Successful treatment of palmar-plantar erythrodysesthesia possibly due to temozolomide with dexamethasone. J Postgrad Med. 2007;53(2):146.

    Article  PubMed  CAS  Google Scholar 

  56. Sarma N. Stevens-Johnson syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. Am J Clin Dermatol. 2009;10(4):264–7.

    Article  PubMed  Google Scholar 

  57. Dissemond J, Hoeft D, Knab J, Franckson T, Kroger K, Goos M. Leg ulcer in a patient associated with hydroxyurea therapy. Int J Dermatol. 2006;45(2):158–60.

    Article  PubMed  Google Scholar 

  58. Neill B, Ryser T, Neill J, Aires D, Rajpara A. A patient case highlighting the myriad of cutaneous adverse effects of prolonged use of hydroxyurea. Dermatol Online J. 2017;23(11):13030.

    Article  PubMed  Google Scholar 

  59. Jeevankumar B, Thappa DM. Blue lunula due to hydroxyurea. J Dermatol. 2003;30(8):628–30.

    Article  PubMed  Google Scholar 

  60. Zargari O, Kimyai-Asadi A, Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia. Pediatr Dermatol. 2004;21(6):633–5.

    Article  PubMed  Google Scholar 

  61. Kluger N, Naud M, Françès P. Toenails melanonychia induced by hydroxyurea. Presse Med (Paris, France: 1983). 2012;41(4):444–5.

    Article  Google Scholar 

  62. Boyd AS, Neldner KH. Hydroxyurea therapy. J Am Acad Dermatol. 1991;25(3):518–24.

    Article  PubMed  CAS  Google Scholar 

  63. Sears ME. Erythema in areas of previous irradiation in patients treated with Hydroxyurea (NSC-32065). Cancer Chemother Rep. 1964;40:31–2.

    PubMed  CAS  Google Scholar 

  64. Bouquet É, Urbanski G, Lavigne C, Lainé-Cessac P. Unexpected drug-induced Raynaud phenomenon: analysis from the French national pharmacovigilance database. Therapie. 2017;72(5):547–54.

    Article  PubMed  Google Scholar 

  65. Chowdhury MM, Patel GK, Inaloz HS, Holt PJ. Hydroxyurea-induced skin disease mimicking the baboon syndrome. Clin Exp Dermatol. 1999;24(4):336–7.

    Article  PubMed  CAS  Google Scholar 

  66. Kazlow DW, Federgrun D, Kurtin S, Lebwohl MG. Cutaneous ulceration caused by methotrexate. J Am Acad Dermatol. 2003;49(2 Suppl Case Reports):S197–8.

    Article  PubMed  Google Scholar 

  67. Del Pozo J, Martínez W, García-Silva J, Almagro M, Peña-Penabad C, Fonseca E. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatol. 2001;11(5):450–2.

    PubMed  Google Scholar 

  68. Khanfir K, Anchisi S. Pemetrexed-associated radiation recall dermatitis. Acta Oncol (Stockholm, Sweden). 2008;47(8):1607–8.

    Article  Google Scholar 

  69. Ge J, Verma V, Hollander A, Langer C, Simone CB. Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review. J Thorac Dis. 2016;8(12):E1589–93.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Kastalli S, Charfi O, Sahnoun R, Lakhoua G. Eyelid and feet edema induced by pemetrexed. Indian J Pharmacol. 2016;48(6):741–2.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Leitman SF, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, Boumpas DT, Illei GG. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion. 2003;43(12):1667–71.

    Article  PubMed  Google Scholar 

  72. Baykal Y, Baykal C, Ozer S, Tulunay G. Topotecan induced nail pigmentation. J Dermatol. 2004;31(11):951–2.

    Article  PubMed  Google Scholar 

  73. Marini M, Wright D, Ropolo M, Abbruzzese M, Casas G. Neutrophilic eccrine hidradenitis secondary to topotecan. J Dermatolog Treat. 2002;13(1):35–7.

    Article  PubMed  CAS  Google Scholar 

  74. Ene-Stroescu D, Ellman MH, Peterson CE. Topotecan and the development of scleroderma or a scleroderma-like illness. Arthritis Rheum. 2002;46(3):844–5.

    Article  PubMed  Google Scholar 

  75. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136(12):1475–80.

    Article  PubMed  CAS  Google Scholar 

  76. Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol. 1999;40(3):367–98. quiz 399–400.

    Article  PubMed  CAS  Google Scholar 

  77. Cohen PR. Paclitaxel-associated reticulate hyperpigmentation: report and review of chemotherapy-induced reticulate hyperpigmentation. World J Clin Cases. 2016;4(12):390–400.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, Roche H, Guenounou S, Recher C, Sibaud V. Chemotherapy-related reticulate hyperpigmentation: a case series and review of the literature. Dermatology (Basel, Switzerland). 2015;231(4):312–8.

    Article  CAS  Google Scholar 

  79. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf. 1995;12(4):245–55.

    Article  PubMed  CAS  Google Scholar 

  80. Luke E. Mitoxantrone-induced extravasation. Oncol Nurs Forum. 2005;32(1):27–9.

    Article  PubMed  Google Scholar 

  81. Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J, McCollough ML, Von Hoff DD. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol. 1995;131(2):202–6.

    Article  PubMed  CAS  Google Scholar 

  82. Makdsi F, Deversa R. Inflammation of actinic keratosis with combination of alkylating and taxane agents: a case report. Cases J. 2009;2:6946.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Ji YZ, Geng L, Qu HM, Zhou HB, Xiao T, Chen HD, Wei HC. Acute generalized exanthematous pustulosis induced by docetaxel. Int J Dermatol. 2011;50(6):763–5.

    Article  PubMed  Google Scholar 

  84. Weinberg JM, Egan CL, Tangoren IA, Li LJ, Laughinghouse KA, Guzzo CA. Generalized pustular dermatosis following paclitaxel therapy. Int J Dermatol. 1997;36(7):559–60.

    Article  PubMed  CAS  Google Scholar 

  85. Kim SW, Lee UH, Jang SJ, Park HS, Kang YS. Acute localized exanthematous pustulosis induced by docetaxel. J Am Acad Dermatol. 2010;63(2):e44–6.

    Article  PubMed  Google Scholar 

  86. Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96(3):824–9.

    Article  PubMed  CAS  Google Scholar 

  87. Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, Gkiozos I, Saif MW, Syrigos KN. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol. 2011;156(3):320–4.

    Article  PubMed  CAS  Google Scholar 

  88. Scotté F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol. 2005;23(19):4424–9.

    Article  PubMed  Google Scholar 

  89. Scotté F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, Banu A, Tourani JM, Andrieu JM, Oudard S. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer. 2008;112(7):1625–31.

    Article  PubMed  Google Scholar 

  90. Gottschling S, Meyer S, Reinhard H, Krenn T, Graf N. First report of a vincristine dose-related Raynaud’s phenomenon in an adolescent with malignant brain tumor. J Pediatr Hematol Oncol. 2004;26(11):768–9.

    Article  PubMed  Google Scholar 

  91. Arias D, Requena L, Hasson A, Gutierrez M, Domine M, Martin L, Barat A. Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine. J Cutan Pathol. 1991;18(5):344–6.

    Article  PubMed  CAS  Google Scholar 

  92. Alimonti A, Nardoni C, Papaldo P, Ferretti G, Caleno MP, Carlini P, Fabi A, Rasio D, Vecchione A, Cognetti F. Nail disorders in a woman treated with ixabepilone for metastatic breast cancer. Anticancer Res. 2005;25(5):3531–2.

    PubMed  Google Scholar 

  93. Goldsmith SM, Sherertz EF, Powell BL, Hurd DD. Cutaneous reactions to azacitidine. Arch Dermatol. 1991;127(12):1847–8.

    Article  PubMed  CAS  Google Scholar 

  94. Tiwari SM, Caccetta T, Kumarasinghe SP, Harvey N. Azacitidine-induced sweet syndrome: two unusual clinical presentations. Australas J Dermatol. 2018;59(3):e224–5.

    Article  PubMed  Google Scholar 

  95. Kawano H, Suzuki T, Ishii S, Wakahashi K, Kawano Y, Sada A, Minagawa K, Ueno D, Yamasaki T, Itoh T, Yokozaki H, Katayama Y. Recurrence of abdominal large-vessel vasculitis and development of severe sweet syndrome after a single cycle of 5-azacytidine in a patient with myelodysplastic syndrome. Eur J Haematol. 2014;92(4):362–4.

    Article  PubMed  Google Scholar 

  96. Assenza B, Tripodi D, Scarano A, Perrotti V, Piattelli A, Iezzi G, D’Ercole S. Bacterial leakage in implants with different implant-abutment connections: an in vitro study. J Periodontol. 2012;83(4):491–7.

    Article  PubMed  Google Scholar 

  97. Trickett HB, Cumpston A, Craig M. Azacitidine-associated Sweet’s syndrome. Am J Health Syst Pharm. 2012;69(10):869–71.

    Article  PubMed  CAS  Google Scholar 

  98. Tintle S, Patel V, Ruskin A, Halasz C. Azacitidine: a new medication associated with sweet syndrome. J Am Acad Dermatol. 2011;64(5):e77–9.

    Article  PubMed  Google Scholar 

  99. Ng ES, Aw DC, Tan KB, Poon ML, Yap ES, Liu TC, Tan LK, Chng WJ, Koh LP. Neutrophilic eccrine hidradenitis associated with decitabine. Leuk Res. 2010;34(5):e130–2.

    Article  PubMed  Google Scholar 

  100. Nouri K, Ricotti CA, Bouzari N, Chen H, Ahn E, Bach A. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide. J Drugs Dermatol. 2006;5(2):182–5.

    PubMed  Google Scholar 

  101. Ruiz-de-Casas A, Carrizosa-Esquivel A, Herrera-Saval A, Rios-Martín JJ, Camacho F. Sézary syndrome associated with granulomatous lesions during treatment with bexarotene. Br J Dermatol. 2006;154(2):372–4.

    Article  PubMed  CAS  Google Scholar 

  102. Shimizu D, Nomura K, Matsuyama R, Matsumoto Y, Ueda K, Masuda K, Taki T, Nishida K, Horiike S, Kishimoto S, Yanagisawa A, Taniwaki M. Scrotal ulcers arising during treatment with all-trans retinoic acid for acute promyelocytic leukemia. Int Med (Tokyo, Japan). 2005;44(5):480–3.

    Article  Google Scholar 

  103. Esser AC, Nossa R, Shoji T, Sapadin AN. All-trans-retinoic acid-induced scrotal ulcerations in a patient with acute promyelocytic leukemia. J Am Acad Dermatol. 2000;43(2 Pt 1):316–7.

    Article  PubMed  CAS  Google Scholar 

  104. Kuo MC, Dunn P, Wu JH, Shih LY. All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia. Ann Hematol. 2004;83(6):376–80.

    Article  PubMed  CAS  Google Scholar 

  105. Jagdeo J, Campbell R, Long T, Muglia J, Telang G, Robinson-Bostom L. Sweet’s syndrome—like neutrophilic lobular panniculitis associated with all-trans-retinoic acid chemotherapy in a patient with acute promyelocytic leukemia. J Am Acad Dermatol. 2007;56(4):690–3.

    Article  PubMed  Google Scholar 

  106. Yanamandra U, Khadwal A, Saikia UN, Malhotra P. Genital vasculitis secondary to all-trans-retinoic-acid. BMJ Case Rep. 2016;2016:bcr2015212205.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Santa Clara Valley Medical Center, San Jose, CA, USA

    Timothy Dang

  2. University of Iowa Health Care, Iowa City, IA, USA

    Hannah Thompson

  3. Department of Dermatology, University of Iowa Health Care, Iowa, IA, USA

    Vincent Liu

  4. Stanford Health Care, Stanford Medicine, Palo Alto, CA, USA

    Bernice Kwong

Authors
  1. Timothy Dang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincent Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernice Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy Dang .

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Iowa Health Care, Iowa, IA, USA

    Vincent Liu

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dang, T., Thompson, H., Liu, V., Kwong, B. (2021). Dermatologic Adverse Effects of Anticancer Therapy II: Cytotoxic Agents. In: Liu, V. (eds) Dermato-Oncology Study Guide. Springer, Cham. https://doi.org/10.1007/978-3-030-53437-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53437-0_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53436-3

  • Online ISBN: 978-3-030-53437-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation